key: cord-0896474-ign5kwh7
authors: Yang, Yang; Gong, Xiaohua; Yang, Liuqing; Li, Jie; Zhang, Jiaqi; Wei, Lanlan; Ye, Guoguo; Tang, Yimin; Jiang, Yujing; Li, Jianhuan; Lin, Yuanlong; Wang, Fuxiang; Lu, Hongzhou; Liu, Yingxia
title: Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees
date: 2022-01-10
journal: J Infect
DOI: 10.1016/j.jinf.2022.01.004
sha: c535c93f8f7d048116819a76e5b597423b106226
doc_id: 896474
cord_uid: ign5kwh7

nan

. Significantly higher ID 50 against both Delta (3.25-fold) and Omicron variants (1.77-fold) were also found in the breakthrough infections (Figure 1D) . For the Beta group, we only got the naive infections, and reduced neutralizing activities were also found with 18.38-fold reduction against the Omicron variant ( Figure 1C) .

In the Vaccinee group, 91.66 (22/24) showed detectable ID 50 against wild type SARS-CoV-2 at 95 days post booster vaccination with GMT of 299, and 1.67-fold, 14.52-fold, 6.73-fold and 3.72-fold reduction against Alpha, Beta, Gamma and Delta variants were found, respectively (Figure 2A) . Notably, only 25% (6/24) of the samples showed detectable ID 50 against Omicron, with 16.07-fold reduction when compared with wild type SARS-CoV-2. We further compared the neutralization activity before and after booster vaccination against different VOCs. After booster vaccination, GMTs of ID 50 against wild type, Alpha, Beta, Gamma, Delta increased 13.47-fold, 8.63-fold, 2.06-fold, 6.75-fold and 3.96 fold, respectively ( Figure 2B) . 

The authors have declared that no conflicts of interest exist. 

The biological and clinical significance of emerging SARS-CoV-2 variants

Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection

Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection